Management & Regulatory

Global Trends in Biopharma Venture Capital: Growth and Caution
Management & Regulatory Global Trends in Biopharma Venture Capital: Growth and Caution

The biopharma sector has experienced a roller coaster of venture capital investments over the past decade and a half. From explosive growth driven by the COVID-19 pandemic to a more selective and strategic investment environment, the landscape continues to evolve rapidly. This article will delve

Eli Lilly Expands Irish Facilities to Boost Global Drug Production
Management & Regulatory Eli Lilly Expands Irish Facilities to Boost Global Drug Production

Eli Lilly has announced substantial investments to expand its manufacturing capabilities in Ireland, with over $1 billion allocated to its Limerick facility and $800 million to its site in Kinsale. These expansions aim to significantly boost production capacities for essential biologic active

Jason Raleigh Purchases $15M in Zenas BioPharma Stock, Boosts Confidence
Management & Regulatory Jason Raleigh Purchases $15M in Zenas BioPharma Stock, Boosts Confidence

Jason Raleigh Purchases $15M in Zenas BioPharma Stock, Boosts Confidence In a remarkable display of confidence, Jason Raleigh, a director at Zenas BioPharma, Inc. (NASDAQ: ZBIO), has made a substantial investment in the company by acquiring $15 million worth of stock. This blockbuster move not only

How Will Richter BioLogics' New Facility Transform Biopharmaceuticals?
Management & Regulatory How Will Richter BioLogics' New Facility Transform Biopharmaceuticals?

The launch of Richter BioLogics' state-of-the-art biopharmaceutical Current Good Manufacturing Practice (cGMP) facility in Bovenau, Germany marks a significant milestone for the company and the industry at large. Positioned as a forefront leader in advanced biopharmaceutical production, the new

Are Zenas Biopharma and Biren Technology Leading the IPO Market Revival?
Management & Regulatory Are Zenas Biopharma and Biren Technology Leading the IPO Market Revival?

The IPO market has faced significant turmoil over the past few years, with many companies postponing or canceling their public offering plans due to weak market conditions. However, recent developments indicate a promising shift. Companies like Zenas Biopharma and Biren Technology are making

Sanofi Boosts Beyfortus Output for RSV Season with FDA Approval
Management & Regulatory Sanofi Boosts Beyfortus Output for RSV Season with FDA Approval

Sanofi is gearing up to address the rising demand for its respiratory syncytial virus (RSV) antibody drug, Beyfortus, by leveraging a recently approved manufacturing line. The company's proactive measures aim to ensure that there is no repeat of last year's shortages, which created significant

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later